Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Assembly Biosciences ( (ASMB) ).
On December 8, 2025, Assembly Biosciences announced positive interim results from Phase 1b clinical studies of its investigational herpes simplex virus (HSV) helicase-primase inhibitors, ABI-1179 and ABI-5366, for recurrent genital herpes. The studies demonstrated significant reductions in HSV-2 shedding rates and virologically confirmed genital lesion rates compared to placebo, with ABI-1179 showing a 98% reduction in shedding rate and ABI-5366 showing a 76% reduction. Both candidates were well-tolerated, and the company is progressing Phase 2 enabling activities for ABI-1179 and planning longer-duration Phase 2 studies for ABI-5366, potentially impacting their market positioning in the antiviral therapeutics sector.
The most recent analyst rating on (ASMB) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.
Spark’s Take on ASMB Stock
According to Spark, TipRanks’ AI Analyst, ASMB is a Neutral.
Assembly Biosciences faces significant financial challenges, with no revenue and persistent losses, heavily impacting its overall score. While technical indicators show bullish momentum, overbought signals suggest caution. Poor valuation metrics further weigh down the score, making it a risky investment.
To see Spark’s full report on ASMB stock, click here.
More about Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics targeting serious viral diseases.
Average Trading Volume: 136,550
Technical Sentiment Signal: Hold
Current Market Cap: $553.8M
Learn more about ASMB stock on TipRanks’ Stock Analysis page.